Viracta Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Viracta Therapeutics generated cash of -$39,892,000, which is less than the previous year. Cash used in financing activities reached the amount of $438,000 last year. Net change in cash is therefore -$24,456,000.
Cash Flow
| 2014 | -43.18M | 3.32M | 46.92M |
|---|---|---|---|
| 2015 | -38.73M | 1.24M | 42.18M |
| 2016 | -36.96M | -14.99M | 33.13M |
| 2017 | -36.14M | 29.74M | 25.31M |
| 2018 | -24.40M | 4.78M | 6.34M |
| 2019 | -22.18M | -16.28M | 43.03M |
| 2020 | -16.05M | -55K | 44.98M |
| 2021 | -18.85M | 12.89M | 62.42M |
| 2022 | -35.45M | -53.86M | 22.54M |
| 2023 | -39.89M | 14.99M | 438K |
VIRX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 36.77M | 103.55M | 47.08M | 18.21M | 13.69M | 26.97M | 8.05M | 26.88M | 22.18M | 15.12M |
Operating activities | ||||||||||
Net income | -51.05M | -49.19M | -114.76M | -19.01M | -23.33M | -26.61M | -35.45M | -38.02M | -36.67M | -43.00M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 492K | 210K | 178K | 32K | 3.13K | 9K | 9K | 11K | 27K | 29K |
Stock-based compensation expense | 7.64M | 13.54M | 5.54M | 348K | 627.61K | 0 | 4.79M | 0 | 6.34M | 0 |
| Deferred income tax benefit | 7.64M | 13.54M | 5.54M | 348K | 627.61K | 0 | 4.79M | 0 | 6.34M | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -98K | -361K | 922K | 969K | -602K | -304K | -174K | -582K | -724K | 2.22M |
Cash generated by operating activities | -39.89M | -35.45M | -18.85M | -16.05M | -22.18M | -24.40M | -36.14M | -36.96M | -38.73M | -43.18M |
Investing activities | ||||||||||
Purchases Of Investments | -67.13M | -70.62M | 0 | -747K | -20.03M | 0 | -35.53M | -35.53M | -35.68M | -42.46M |
Investments In Property Plant And Equipment | -138K | -45K | -4.25M | -55K | 0 | 0 | -26K | 0 | 0 | -48K |
Acquisitions Net | 0 | 0 | 17.14M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 14.99M | -53.86M | 12.89M | -55K | -16.28M | 4.78M | 29.74M | -14.99M | 1.24M | 3.32M |
Financing activities | ||||||||||
Common Stock Issued | 299K | 2.33M | 62.32M | 851K | 45.08M | 6.34M | 32.93M | 26.38M | 43.82M | 54.31M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 19.98M | -234K | -44.13M | -2.04M | 0 | -7.61M | -6.75M | -1.64M | -9.35M |
Cash used in financing activities | 438K | 22.54M | 62.42M | 44.98M | 43.03M | 6.34M | 25.31M | 33.13M | 42.18M | 46.92M |
Net Change In Cash | -24.45M | -66.78M | 56.46M | 28.87M | 4.56M | -13.28M | 18.92M | -18.83M | 4.7M | 7.06M |
Cash at end of period | 12.31M | 36.77M | 103.55M | 47.08M | 18.26M | 13.69M | 26.97M | 8.05M | 26.88M | 22.18M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |